NASDAQ:DXR Daxor Q2 2025 Earnings Report $10.66 +0.56 (+5.49%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Daxor EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADaxor Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADaxor Announcement DetailsQuarterQ2 2025Date3/2/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsDaxor's Q2 2026 earnings is estimated for Thursday, August 20, 2026, based on past reporting schedulesConference Call ResourcesEarnings HistoryCompany Profile Daxor Earnings HeadlinesDaxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, TexasJuly 7, 2026 | globenewswire.comDaxor Stock Dividends | NASDAQ:DXR | BenzingaJune 26, 2026 | benzinga.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.July 14 at 1:00 AM | American Alternative (Ad)Daxor Shareholders Reelect Board and Ratify AuditorJune 24, 2026 | tipranks.comDaxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume MonitorJune 2, 2026 | globenewswire.comDaxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume AnalysisApril 28, 2026 | markets.businessinsider.comSee More Daxor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email. Email Address About DaxorDaxor (NASDAQ:DXR) is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload. In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency. Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.View Daxor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Prepare for the Next Wave of Factory Automation With These 3 Standout NamesAnalysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software Costs Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
